Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Medical Oncology
Would you consider lenvatinib plus everolimus as first line treatment for a patient with tuberous sclerosis and metastatic renal cell carcinoma?
Related Questions
Do you offer neoadjuvant chemotherapy to nested variant urothelial carcinoma (NVUC) of the bladder?
What data support the use of continuing GnRH therapy "backbone" in metastatic castration resistant prostate cancer (mCRPC) receiving additional therapies?
Do you recommend any alternative schedule for cabozantinib to make treatment compliance easier for patients with metastatic renal cell carcinoma?
What adjuvant therapy, if any, is best for mucinous tubular and spindle cell carcinoma of the kidney?
How do you treat metastatic large cell neuroendocrine carcinoma of prostate with undetectable PSA, who had the treatment related transformation while on ADT monotherapy?
Would you consider neoadjuvant immunotherapy in a patient with Lynch syndrome and urothelial cancer?
What chemotherapy regimen do you use for de novo metastatic squamous cell carcinoma of penile urethra?
Given results of the RADICALS trials, is LT-ADT standard of care for salvage prostate RT?
How often do you monitor for pancreatitis (check lipase/amylase) while on Axitinib?
What is your preferred choice of therapy for first-line treatment of a patient with good, intermediate, or poor risk stage III nonseminomatous germ cell tumor if the patient is truly cisplatin-ineligible?
